HomeNRSNW • NASDAQ
add
NeuroSense Therapeutics
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | — | — |
Operating expense | 3.03M | 11.40% |
Net income | -857.00K | 68.03% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -3.02M | -11.38% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 1.21M | -82.96% |
Total assets | 1.84M | -76.60% |
Total liabilities | 3.54M | -62.35% |
Total equity | -1.70M | — |
Shares outstanding | 18.06M | — |
Price to book | -1.56 | — |
Return on assets | -460.91% | — |
Return on capital | 176.06% | — |
Cash Flow
Net change in cash
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Net income | -857.00K | 68.03% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Founded
2017
Website
Employees
18